Results 321 to 330 of about 76,034 (338)
Some of the next articles are maybe not open access.
Clinica Chimica Acta, 2015
Apolipoprotein M (ApoM) is a novel apolipoprotein that was discovered in 1999 and is bound primarily to high-density lipoproteins (HDLs) in the plasma. Multiple factors may influence its expression at both the post-transcriptional and the transcriptional levels both in vivo and ex vivo as follows: hepatocyte nuclear factor-1α, 4α (HNF-1α, 4α), liver ...
Kun, Ren +4 more
openaire +2 more sources
Apolipoprotein M (ApoM) is a novel apolipoprotein that was discovered in 1999 and is bound primarily to high-density lipoproteins (HDLs) in the plasma. Multiple factors may influence its expression at both the post-transcriptional and the transcriptional levels both in vivo and ex vivo as follows: hepatocyte nuclear factor-1α, 4α (HNF-1α, 4α), liver ...
Kun, Ren +4 more
openaire +2 more sources
2003
The apolipoproteins associated with serum lipoprotein particles give structural stability as well as regulatory control in lipid metabolism. The development of atherosclerosis is linked to dysfunction in lipid metabolism, and the serum lipoproteins are directly involved, either through the action of their apolipoprotein components or in combination ...
L K, Watkins +2 more
openaire +2 more sources
The apolipoproteins associated with serum lipoprotein particles give structural stability as well as regulatory control in lipid metabolism. The development of atherosclerosis is linked to dysfunction in lipid metabolism, and the serum lipoproteins are directly involved, either through the action of their apolipoprotein components or in combination ...
L K, Watkins +2 more
openaire +2 more sources
Apolipoprotein(a): structure and biology
Frontiers in Bioscience, 2001Apolipoprotein(a), apo(a), the distinctive glycoprotein constituent of lipoprotein(a), Lp(a), is synthesized in the liver, links covalently to apoB100-lipoprotein, and travels so linked in the plasma to tissue sites where removal mechanisms are yet undetermined.
Scanu Am, Edelstein C, Nakajima K
openaire +3 more sources
Apolipoprotein Mutants and Apolipoprotein Disorders
1983A high degree of increased differentiation has come to the field of genetic dyslipoproteinemia. Most of the classical lipoprotein phenotypes have been shown to be genotypically heterogenous or subject to allelism. Characterization of the various apolipoproteins, of cellular lipoprotein receptors and of enzymes catalyzing intravascular changes in ...
openaire +2 more sources
Mutants of Apolipoproteins A and C
1986The determination of the circulating levels of apolipoproteins has become common practice in clinical laboratories, in view of the apparent correlation between levels of specific apolipoproteins and increased or decreased cardiovascular risk [1, 2].
C. R. Sirtori, M. R. Lovati
openaire +4 more sources
Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease
Current Opinion in Clinical Nutrition and Metabolic Care, 2003Apolipoproteins and their receptors are the main controllers of lipid metabolism and, as such, have a major impact not only on the risk of cardiovascular disease but also on the development and degeneration of the central nervous system. Variations in the genes coding for these apolipoproteins and their receptors and the interaction with the ...
Joan-Carles Vallvé +3 more
openaire +2 more sources
ApolipoproteinE and Alzheimer's Disease [PDF]
Biochemical Society Transactions, 1996 Abstract: The specific molecular pathway by which apolipoprotein E modifies the expression of Alzheimer's disease remains elusive. Isoform‐ specific interactions of apolipoprotein E with other molecules determine the outcome from other neurologic disorders and may provide more tractable model systems.
openaire +4 more sources
Apolipoprotein L1 and apolipoprotein A-IV and their association with kidney function
Current Opinion in Lipidology, 2017Purpose of review Chronic kidney disease (CKD) is a common disease with an estimated prevalence of 10–12%. There are pronounced differences between ethnicities with a 3-fold to 4-fold higher lifetime risk for end-stage kidney disease in African Americans compared to European Americans.
openaire +3 more sources
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1996
M F Laker, K Evans
openaire +3 more sources
M F Laker, K Evans
openaire +3 more sources